
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is positioned favorably due to its potential for significant upside based on current valuations, which are deemed attractive. The company's development of innovative therapeutics, particularly in breast cancer and COVID-19 treatment, signifies its focus on addressing unmet medical needs, which could drive future growth. Furthermore, the expected clinical milestones and resulting data releases are identified as likely catalysts that could positively influence the stock's performance.
Bears say
Atossa Therapeutics faced a net loss of $8.7 million, translating to an earnings per share (EPS) of $(0.07), which matched the forecasts yet indicated ongoing financial challenges. The company reported consistent losses over successive periods, reinforcing concerns regarding its financial stability amid a demanding clinical development landscape. Additionally, significant risks are identified in clinical trial outcomes, regulatory approval processes, and market commercialization, all of which could adversely impact future liquidity and overall investor confidence in the stock.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares